Method for screening anthracycline cardiotoxicity genes through mRNA expression profiles and competitive endogenesis RNA expression profiles jointly

Abstract

The invention relates to a method for screening anthracycline cardiotoxicity genes through mRNA expression profiles and competitive endogenesis RNA expression profiles jointly. The method includes the steps that expression values of a large quantity of genes are detected through mRNA and competitive endogenesis RNA expression profile chips, and the correlations of all the genes are ordered; the obtained mRNA feature genes and the obtained competitive endogenesis RNA feature genes are combined; a gene pool is subjected to further gene selection with a genetic algorithm; differential expression genes are selected by comparing the data between different samples of mRNA and competitive endogenesis RNA joint expression profiles of breast cancer patients, breast cancer AIC patients and able-bodied persons; the differential expression genes are predicted, and the genes with the scores larger than 140 and free energy smaller than 20 are selected as reliable target genes; genes with obvious differences are selected from the target genes, and constructed breast-cancer anthracycline cardiotoxicity attacking target genes are verified through the residual RNA. By means of the method, more reliable potential gene markers related to anthracycline cardiotoxicity can be selected as a candidate.

Description

technical field

[0001] The invention relates to the technical field of gene expression profile analysis, in particular to a method for jointly screening anthracycline cardiotoxicity genes by using mRNA expression profile and competitive endogenous RNA expression profile. Background technique

[0002] About 81.4% of all invasive breast cancer patients in China received adjuvant chemotherapy and had a high tumor cure rate. However, long-term survivors of breast cancer patients currently have problems: the mortality rate due to cardiac causes is 8.2 times higher; long-term survivors have a 15-fold higher risk of heart failure and a 10-fold higher risk of cardiovascular disease. According to the 2015 NCCN guidelines for breast cancer, the preferred adjuvant chemotherapy regimen is AC×4→T(P)×4 (pirarubicin / cyclophosphamide-paclitaxel). Anthracyclines have broad antitumor spectrum and strong antitumor activity. Received high evaluation in chemotherapy. The most prominent chemoth...

Images